Oral GLP-1 Formulations and Future Projections Several companies are developing oral GLP-1 formulations, including Novo Nordisk, Pfizer, and smaller firms, positioning them as potential acquisition targets
Despite it being sometimes referred to as one, Zepbound is not just a GLP-1 receptor agonist, which includes medications like Ozempic and Wegovy
The 2026 Prohibited List: International Standard
Ozempic is a GLP-1 receptor agonist, while Mounjaro is a dual GLP-1/GIP agonist
Compounded medications are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality
We need real-world evidence